

021104

23026 U.S. PTO

PTO/SB/05 (06-03)

Approved for use through 07/31/2003. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonapplications under 37C.F.R. §1.53(b))

Attorney Docket No. **PC19074**First Inventor **WESLEY K. M. CHONG**Title **ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE**Express Mail Label No. **EI 969716381****APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:  
Mail Stop Patent Applications  
Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)
2. <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
3. <input checked="" type="checkbox"/> Specification [Total Pages <b>177</b> ] (preferred arrangement set forth below) <ul style="list-style-type: none"> <li>- Descriptive title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R&amp;D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>	a. <input type="checkbox"/> Computer Readable Copy (CRF)
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets <b>—</b> ]	b. Specification Sequence Listing on: <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies)</li> <li>ii. <input type="checkbox"/> Paper</li> </ul>
5. <input checked="" type="checkbox"/> Oath or Declaration [Total pages <b>2</b> ] a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 18 completed) i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	c. <input type="checkbox"/> Statement verifying identity of above copies
6.. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
18. If a <b>CONTINUING APPLICATION</b> , check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney (when there is an assignee)
	11. <input type="checkbox"/> English Translation Document (if applicable)
	12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
	13. <input type="checkbox"/> Preliminary Amendment
	14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
	15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
	16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
	17. <input type="checkbox"/> Other:

**ACCOMPANYING APPLICATION PARTS**

9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney (when there is an assignee)
11. <input type="checkbox"/> English Translation Document (if applicable)	12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
13. <input type="checkbox"/> Preliminary Amendment	14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. <input type="checkbox"/> Other:	

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.
 Continuation     Divisional     Continuation-in-part (CIP)    of prior application No: **— / —**
Prior application information: **Examiner** \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**19. CORRESPONDENCE ADDRESS**

<input checked="" type="checkbox"/> Customer Number	<b>28940</b>	<input type="checkbox"/> or <input type="checkbox"/> Correspondence address below
Name		
Address		
City	State	Zip Code
Country	Telephone	Fax

NAME (Print/type)	Wendy L. Hsu	Registration No. (Attorney/Agent)	42,794
Signature	<i>Wendy L. Hsu</i>	Date	2/11/04

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for

17858 U.S. PTO  
10/776450  
021104

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# FEE TRANSMITTAL

## for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small status. See 37 CFR 1.27**Total Amount of Payment**  Attorney Docket No. **METHOD OF PAYMENT** (check all that apply) Check  Credit Card  Money  Other  None  
Order Deposit Account: 500329 Agouron Pharmaceuticals, Inc.**The Director is authorized to:** (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee  
 to the above-identified deposit account.

**FEE CALCULATION****1. BASIC FILING FEE****Large Entity**  **Small Entity** 

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	<b>770</b>
1002	340	2002	170	Design filing fee	
1003	530	2203	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	filings fee	
<b>Subtotal (1)s</b>				<b>\$ 770</b>	

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

	Extra Claims	Fee from below	Fee Paid
Total Claims	9	- 20** = 0	x 0 = 0
Independent Claims	3	- 3 = 0	x 0 = 0
Multiple Dependent			0 = 0

**Large Entity**  **Small Entity** 

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue independent claims over original patent


 (\$)-0-

\*\*or number previously paid, if greater; For Reissues, see above

Complete if Known									
Application Number		TBA							
Filing Date		Herewith							
First Named Inventor		WESLEY K. M. CHONG							
Examiner Name		TBA							
Art Unit		TBA							
PC		PC19074							
FEE CALCULATION (continued)									
3. ADDITIONAL FEES									
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)				
		1051	130	2051	65				
		1052	50	2052	25				
		1053	130	1053	130				
		1812	2,520	1812	2,520				
		1804	920*	1804	920*				
		1805	1,840*	1805	1,840*				
		1251	110	2251	55				
		1252	420	2252	210				
		1253	950	2253	475				
		1254	1,480	2254	740				
		1255	2,010	2255	1,005				
		1401	330	2401	165				
		1402	330	2402	165				
		1403	290	2403	145				
		1451	1,510	1451	1,510				
		1452	110	2452	55				
		1453	1,330	2453	665				
		1501	1,330	2501	665				
		1502	480	2502	240				
		1503	640	2503	320				
		1460	130	1460	130				
		1807	50	1807	50				
		1806	180	1806	180				
		8021	40	8021	40				
		1809	770	2809	385				
		1810	770	2810	385				
		1801	770	2801	385				
		1802	900	1802	900				
		Other Fee (specify) _____							
		*Reduced by Basic Filing Fee Paid							
		Subtotal (3)							
		(\$)-0-							

**SUBMITTED BY** 

(Complete if applicable)

Name (Printed/Type)	Wendy L. Hsu	Registration No. (Attorney Agent)	42,794	Telephone	858-526-4652
Signature					

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file ( and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.

Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail : EC 969716381 US in an envelope addressed to: Mail Stop: Patent Applications, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 11th day of February 2004.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re the Application of:**  
**WESLEY K. M. CHONG, ET AL**

**Serial No.: Not Yet Assigned**

**Filed: Herewith**

**For: ANTIPIROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE**

**Group Art Unit: Not Yet Assigned**

**Examiner: Not Yet Assigned**

Mail Stop: Patent Applications  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

1. Application Data Sheet	3 pages;
2. Utility Patent Application Transmittal 1 page;	
3. Fee Transmittal	1 page;
4. Declaration	14 pages;
5. Power of Attorney	7 pages;
6. Specification	177 pages;
• Claims	16 pages;
• Abstract	1 page;
9. Return Postcard	1 card; and
10. Total Fee Due \$770.00	Deposit Account

Respectfully submitted,

Date: 2/11/04

Wendy L. Hsu  
Wendy L. Hsu  
Attorney For Applicants  
Registration No. 42,794

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4652  
Fax: (858) 678-8233